Pathophysiology of Inflammatory Bowel Diseases

2020/12/30 by John T. Chang · 4 citations
Biochemistry, Genetics and Molecular Biology · Medicine · #Gastrointestinal motility and disorders #Inflammatory Bowel Disease #Microscopic Colitis

paper · doi:10.1056/nejmra2002697

openalex publication_date 2020/12/30 · openalex created_date 2025/10/10 · openalex updated_date 2026/07/29

Abstract

Research on IBDs has identified disrupted immune responses in the gastrointestinal mucosa and putative disruptions in the gut microbiome as causative agents. This work has led to better therapeutic control of IBDs with the use of various antiinflammatory agents.

Citations

• Randomised placebo-controlled trial of rituximab (anti-CD20) in active ulcerative colitis

Cited by

• A systematic framework for understanding the microbiome in human health and disease: from basic principles to clinical translation
• Single-Cell Transcriptomic Profile of Innate Cell Populations in Mesenteric Lymph Nodes of Inflammatory Bowel Disease Patients
• Bile acid 7α-dehydroxylating bacteria accelerate injury-induced mucosal healing in the colon
• ACSS2-mediated lysine crotonylation attenuates senescence and enhances the therapeutic efficacy of adipose-derived stem cells in inflammatory bowel disease

Related

• Inflammatory bowel diseases: pathological mechanisms and therapeutic perspectives
• The Gut Microbiome and Inflammatory Bowel Diseases
• B cells in inflammatory bowel disease
• The Interplay Between Immunological Status and Gut Microbial Dysbiosis in the Development of the Symptoms of Irritable Bowel Syndrome: A Systematic Review with Meta-Analysis
• Gut microbiota, intestinal permeability, and systemic inflammation: a narrative review